Q-omics provides the consensus-scored HEPACAM profile across patient tissues and cancer cell-line models. HEPACAM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HEPACAM is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, HEPACAM RNA expression shows 8,763 significant gene co-expression associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where HEPACAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEPACAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEPACAM survival associations across molecular data types. HEPACAM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEPACAM RNA expression–survival associations across cancer types. High HEPACAM expression shows unfavorable associations in KIRC, CESC and HNSC, but favorable associations in ESCA, SKCM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HEPACAM RNA expression.
This table summarizes HEPACAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HEPACAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEPACAM shows lower tumor expression in COAD, THCA, KIRP, BLCA, BRCA and KICH. The COAD box plot shows higher HEPACAM RNA expression in normal versus tumor tissue (log2 FC = −0.188, t-test p < 0.001).
This table shows molecular features associated with HEPACAM in patient tissues and cancer cell lines. In patient samples, HEPACAM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HEPACAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
